The portfolio continues to invest in companies we believe are strong and improving but whose share price performance does not ...

The portfolio continues to invest in companies we believe are strong and improving and have improvement that is sustainable.

Nasdaq 100, S&P 500, Dow Jones Industrial Average, Microsoft Corporation. Read 's Market Analysis on Investing.com ...

There is increased use of quadruple medical therapy among patients following implementation of an HF quality improvement initiative.

Pfizer’s PFE stock has declined 10.7% so far this year compared with a decrease of 7.7% for the industry. The stock has also ...

Drugmaker Novo Nordisk is once again Europe's largest company by market capitalisation, rising above German software firm SAP ...

Novo Nordisk said on Thursday it plans to start late-stage trials of amycretin injection and oral drugs during the first ...

Wegovy maker Novo Nordisk is moving its investigational amycretin asset into late-stage weight loss trials starting early ...

Novo Nordisk is progressing both subcutaneous and oral versions of amycretin into Phase III trials for patients with obesity ...

Novo Nordisk has launched a direct-to-consumer (DTC) option for uninsured or under-insured people wanting to access its GLP-1 agonist weight-loss drug Wegovy, cutting the drug's price in half to $ ...

(Reuters) -Novo Nordisk said on Thursday it plans to start late-stage trials of amycretin injection and oral drugs during the ...

The Global Digital Diabetes Management Market is expected to grow at a rate of 20% by 2026. Growing adoption of data analytics & artificial intelligence in digital diabetes management & diabetes care ...